Category - Developments

Developments

Lobo Genetics going public in RTO of Cassowary Capital

Closely-held Lobo Genetics entered into a non-binding letter of intent with Cassowary Capital (TSXV:BIRD) that will result in a reverse takeover of Cassowary by Lobo. Cassowary is a capital pool company on the TSX...

November 22, 2018

Developments

FDA accepts IntelGenx NDA resubmission for RIZAPORT

The FDA accepted IntelGenx’s (TSXV:IGX; OTCQX: IGXT) 505(b)(2) NDA resubmission of RIZAPORT oral soluble film 10 mg for the treatment of acute migraines. The FDA also assigned a Prescription Drug User Fee Act (PDUFA)...

November 20, 2018

Developments

IntelGenx gains media attention for VersaFilm delivery of cannabis

The Canada Pot Talks radio show has interviewed Horst Zerbe, president and CEO of IntelGenx (TSXV:IGX; OTCQX:IGXT), about its partnership with Tilray (NASDAQ:TLRY) to co-develop and commercializean IntelGenx VersaFilm...

November 20, 2018

Developments

Canopy Growth affiliate receives Health Canada cannabis license

Canopy Rivers’ (TSXV:RIV) portfolio company, Radicle Medical Marijuana, received a production and sales licence from Health Canada to supply and sell finished cannabis products for both the medical and adult-use market...

November 19, 2018

Developments

Tilray makes strategic investment in IntelGenx

IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT) closed a private placement with Tilray (NASDAQ:TLRY) in connection with the companies’ partnershipto co-develop and commercialize IntelGenx’s VersaFilm oral film product...

November 14, 2018

Developments

Analysts highlight potential of Profound Medical’s TULSA-PRO to treat BPH in addition to localized prostate cancer

Analysts for Canaccord Genuity, Echelon Wealth Partners and A.G.P./Alliance Global Partners are raising the prospects of Profound Medical’s (OTCQX:PRFMF; TSX:PRN) TULSA-PRO device as a treatment for benign prostatic...

November 12, 2018

Developments

IntelGenx, Tilray in definitive partnership for cannabis VersaFilm products

IntelGenx (TSXV:IGX; OTCQX:IGXT) and Tilray (NASDAQ:TLRY) signed a definitive license, development and supply agreement to co-develop and commercialize oral film VersaFilm products infused with adult-use and medical...

November 7, 2018

Developments

Constellation Brands closes $5-billion investment in Canopy Growth

Constellation Brands (NYSE:STZ) closed its $5-billion (Canadian) investment in Canopy Growth (TSX:WEED; NYSE:CGC) following approval by Canopy shareholders and all regulatory agencies, including the Canadian government...

November 1, 2018

Developments

elminda, Villages Health joint study receives Erickson Foundation aging award

A joint research project between closely-held elminda of Israel and The Villages Health of Florida will receive the prestigious Erickson Foundation Award for Excellence in Aging Research at the upcoming 2018 American...

November 1, 2018

Developments

Scientus Pharma updates buccal cannabis spray development collaboration with Generex

Closely-held Scientus Pharma updated its collaboration with Generex Biotechnology (OTCQB:GNBT) to co-develop products for the delivery of cannabinoids via the buccal mucosa, or inner lining of the mouth. Having recently...

October 31, 2018

Category - Developments

Lobo Genetics going public in RTO of Cassowary Capital

FDA accepts IntelGenx NDA resubmission for RIZAPORT

IntelGenx gains media attention for VersaFilm delivery of cannabis

Canopy Growth affiliate receives Health Canada cannabis license

Tilray makes strategic investment in IntelGenx

Analysts highlight potential of Profound Medical’s TULSA-PRO to treat BPH in addition to localized prostate cancer

IntelGenx, Tilray in definitive partnership for cannabis VersaFilm products

Constellation Brands closes $5-billion investment in Canopy Growth

elminda, Villages Health joint study receives Erickson Foundation aging award

Scientus Pharma updates buccal cannabis spray development collaboration with Generex

General

More